Alto Neuroscience, Inc.ANRONYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.28% | +0.38% | +0.61% | +0.45% | +0.54% |
| Weighted Average Shares Diluted Growth | +0.28% | +0.38% | +0.61% | +0.45% | +0.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +259.92% | +104.95% | -18.11% | -20.01% | -23.28% |
| Book Value per Share Growth | +0.00% | +0.00% | -28.41% | -31.66% | -32.77% |
| Debt Growth | +68.65% | +69.68% | +164.04% | +171.52% | +63.96% |
| R&D Expense Growth | +63.93% | +12.00% | +0.22% | -0.46% | -19.41% |
| SG&A Expenses Growth | +232.72% | +196.90% | +31.47% | +7.78% | -26.85% |